Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906087 · ClinicalTrials.gov registry record · Phase 4
Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00906087 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 14 participants.
The verdict
NCT00906087, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a combination medication called Cosopt® (Merck \& Co., Inc.).
Interventions
- DRUG Cosopt (combination eyedrop of dorzolamide and timolol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-08-04 |
| Est. Completion | 2012-07-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00906087
The ClinicalTrials.gov registry entry for NCT00906087 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cosopt (combination eyedrop of dorzolamide and timolol) is the first listed.
NCT00906087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00906087 about?
NCT00906087 is a clinical study titled "Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions". The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a combination medicatio...
What is the current status of trial NCT00906087?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2009-08-04. Estimated completion is 2012-07-18.
What interventions are being tested in trial NCT00906087?
The interventions under investigation include: Cosopt (combination eyedrop of dorzolamide and timolol) (DRUG).
Who is sponsoring clinical trial NCT00906087?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.